As part of the Clinical Trials Digital Week, KNect365 Life Sciences organised a global 4-day series of live educational webcasts and showcased a EPAD webinar. Downloadable resources providing the latest insights into clinical partnerships, outsourcing, operations and technology from 13-16 May 2019 are now available.
KNect365 Life Sciences (formerly IBC Life Sciences and IIR Pharma) provides the industry with opportunities to connect with people, ideas, data and technology to fast-track therapeutic developments, maximize commerciality and improve patient outcomes. KNect365 Life Sciences is a global community of Scientists, Executives, Regulators, Technologists and Academics.
Katrin Haeverans (Clinical Scientist and External Affairs Director at Janssen) was invited to deliver a webinar on the European Prevention of Alzheimer’s Dementia Consortium (EPAD) project. She introduced the project, its objectives, design and consortium. Then, she mentioned the EPAD Longitudinal Cohort Study (LCS) where research participants are invited to join a cohort of at-risk subjects and detailed the EPAD Proof of Concept (PoC) platform.
The EPAD platform has been developed to speed up the development of effective, safe medicines which slow or prevent the development of Alzheimer’s dementia. By setting up a trial-ready cohort of research participants, creating a pan-European network of trial sites, identifying ineffective medicines earlier in the development process and eliminating failures in more advanced (Phase III) trials, EPAD aims to accelerate the development of effective therapies. Katrin Haeverans closed her talk by reporting some operational challenges and the added value for pharma companies.
If you have missed the event, you can read the blog post “Accelerating Alzheimer’s dementia research with collaborative research design” published on the KNect365 website. You can also watch the full on-demand webinar here.
This post has been provided by the EPAD project: http://ep-ad.org/knect365-webinar-on-epad-is-now-available/